title: Does serum soluble vascular endothelial growth factor levels have different importance in pediatric acute leukemia and malignant lymphoma patients?
abstract: Vascular endothelial growth factor (VEGF) seems to play a central role in angiogenesis-lymphangiogenesis in hematological malignancies. There are limited data related to childhood hematologic malignancies. The aim of the study was to evaluate soluble VEGF (sVEGF) levels in children with acute leukemia and malignant lymphoma (ML) at diagnosis and in remission. The levels of serum sVEGF were measured by enzyme-linked immunosorbent assay (ELISA) in 20 children with acute leukemia, 33 children with different histopathological subtypes of ML, and 20 healthy controls. The levels of sVEGF at diagnosis (range 2 -1040 pg/mL; median 52 pg/mL) was significantly lower than in remission (range 136 -1960 pg/mL; median 630 pg/mL) in acute myeloid leukemia (AML) group (P = .018). The sVEGF levels at diagnosis (range: 2 -640 pg/mL; median 89 pg/mL) was significantly lower compared to remission values (range: 116 -1960 pg/mL; median 136 pg/mL) in patients with acute lymphoblastic leukemia (ALL) (P = .002). In ML group, including Burkitt's lymphoma (BL), T-cell non-Hodgkin's lymphoma (NHL), and Hodgkin's lymphoma (HL), sVEGF levels at diagnosis were higher than remission levels, but there was no statistically significant difference (P >.05). On the other hand, there were significant difference between levels in active disease and control group, ie, BL versus control, T-cell NHL versus control, and HL versus control (P = .008, P = .043, P = .007, respectively). The authors noticed that sVEGF levels showed distinct behavioral pattern in different childhood malignancies at diagnosis and in remission. In acute leukemia and ML patients, VEGF acts through different pathophysiological mechanisms, in both bone marrow (BM) angiogenesis and lymphoid tissue lymphangiogenesis.
authors.affiliation: Department of Pediatric Oncology, Ankara University School of Medicine, Ankara, Turkey. handanprl@hotmail.com
authors.forename: Handan Ugur
authors.initials: HU
authors.lastname: Dincaslan
authors.forename: Gulsan
authors.initials: G
authors.lastname: Yavuz
authors.forename: Emel
authors.initials: E
authors.lastname: Unal
authors.forename: Nurdan
authors.initials: N
authors.lastname: Tacyildiz
authors.forename: Aydan
authors.initials: A
authors.lastname: Ikinciogullari
authors.forename: Figen
authors.initials: F
authors.lastname: Dogu
authors.forename: Deniz
authors.initials: D
authors.lastname: Guloglu
authors.forename: Nazmiye
authors.initials: N
authors.lastname: Yuksek
authors.forename: Ulya
authors.initials: U
authors.lastname: Ertem
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D005260:Female; D006689:Hodgkin Disease / Q000097:blood* / Q000175:diagnosis / Q000628:therapy; D006801:Humans; D007223:Infant; D015470:Leukemia, Myeloid, Acute / Q000097:blood* / Q000175:diagnosis / Q000628:therapy; D008228:Lymphoma, Non-Hodgkin / Q000097:blood* / Q000175:diagnosis / Q000628:therapy; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000097:blood* / Q000175:diagnosis / Q000628:therapy; D012074:Remission Induction; D012680:Sensitivity and Specificity; D012995:Solubility; D042442:Vascular Endothelial Growth Factors / Q000097:blood*
chemical_list: D042442:Vascular Endothelial Growth Factors